2014 Conference Videos
Conference Highlights
The Turning the Tide Against Cancer Through Sustained Medical Innovation national conference was held on October 9, 2014 in Washington, D.C. Stakeholders and thought leaders in the health policy and cancer communities convened to discuss and explore specific policy pathways aimed at supporting the shift to patient-centered cancer research and care and addressing the value and cost of cancer care.
Welcome and Introductory Remarks
Edward Abrahams, Ph.D., President, Personalized Medicine Coalition, delivers opening remarks at the second Turning the Tide Against Cancer Through Sustained Medical Innovation national conference in Washington, D.C. on October 9, 2014.
Tackling the Complexity of Cancer: Finding Common Ground on Value and Progress
Cancer is a complex disease that places a substantial emotional, physical, and financial burden on patients, their families, payers, and society. The incidence of cancers is predicted to increase over the next 20 years, compelling us to find solutions that help sustain innovation and deliver better outcomes to patients. In this session, experts with seemingly divergent points of view find common ground on defining and rewarding value in oncology, developing new treatments, and learning from our successes and failures.
Patient-Centered Clinical Development Models
Randomized, controlled studies have historically been considered the gold standard in biomedical research. As science advances and our healthcare system evolves to be more patient-centered, we must reevaluate our process for studying and assessing new cancer treatments. In this spotlight session, Roy S. Herbst, M.D., Ph.D., Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research, Yale Comprehensive Cancer Center and Yale School of Medicine, highlights the Lung Cancer Master Protocol, an example of a clinical development model designed to provide patients with better access to new treatments.
Supporting the Shift to Patient-Centered Cancer Research and Care
Continuing to improve the quality and value of cancer research while addressing rising healthcare costs is a daunting challenge. To get it right, we must shift our approach to one that is more patient-centric and considers an individual patient’s disease, preferences, and values. This panel discussion explores ways to best support patient-centeredness and patient engagement as part of optimal cancer research and care, including the use of tools that facilitate patient participation and support informed decision-making.
Building a Research Base in Support of Innovative Cancer Care
Continued innovation in cancer treatment requires a clear understanding of the value of new technologies and advances in care delivery. Demonstrating and quantifying value is extremely important but also challenging due to the complexity of cancer care and diversity of patient needs. In this spotlight session, John J. Castellani, President and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA), highlights recent grants from the PhRMA Foundation and other current initiatives to assess the social and economic benefits of new cancer treatments.
Addressing Value and Cost of Cancer Care
Innovation and scientific advances are improving the way we detect, diagnose, and treat cancer, giving patients greater hope. However, this progress is occurring in a time of intense pressure to contain rising healthcare costs. Panelists discuss the policy solutions needed to sustain innovation and move us towards a more high-value, patient-centric system of cancer care.
The Role of Payment Reforms in Supporting Innovative Cancer Care
Payers and healthcare systems are increasingly turning to incentive-based models to reward physicians for improving quality and outcomes and reducing the total cost of cancer care. In this spotlight session, Jennifer Malin, M.D., Ph.D., Medical Director for Oncology for Cancer Survivorship, WellPoint, Inc., and Shelley Fuld Nasso, CEO, National Coalition for Cancer Survivorship, examine incentive structures, including the WellPoint Cancer Care Quality Program, and their impact on innovation in the clinic.
Call to Action and Conference Closing
Amy M. Miller, Ph.D., Executive Vice President, Personalized Medicine Coalition, delivers closing remarks at the second Turning the Tide Against Cancer Through Sustained Medical Innovation national conference in Washington, D.C. on October 9, 2014.
